Tudor Investment Corp ET AL Takes $450,000 Position in Tango Therapeutics, Inc. $TNGX

Tudor Investment Corp ET AL bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 53,572 shares of the company’s stock, valued at approximately $450,000.

Several other large investors have also modified their holdings of the stock. Invesco Ltd. boosted its position in Tango Therapeutics by 138.8% during the 1st quarter. Invesco Ltd. now owns 70,517 shares of the company’s stock valued at $97,000 after purchasing an additional 40,983 shares during the period. AQR Capital Management LLC bought a new position in shares of Tango Therapeutics in the first quarter valued at approximately $195,000. Dynamic Technology Lab Private Ltd boosted its stake in shares of Tango Therapeutics by 139.7% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock worth $35,000 after acquiring an additional 15,037 shares in the last quarter. Woodline Partners LP boosted its stake in shares of Tango Therapeutics by 28.3% during the 1st quarter. Woodline Partners LP now owns 506,188 shares of the company’s stock worth $693,000 after acquiring an additional 111,791 shares in the last quarter. Finally, Jane Street Group LLC grew its holdings in shares of Tango Therapeutics by 270.6% in the 1st quarter. Jane Street Group LLC now owns 352,897 shares of the company’s stock worth $483,000 after acquiring an additional 257,668 shares during the last quarter. Institutional investors own 78.99% of the company’s stock.

Tango Therapeutics Stock Performance

Shares of NASDAQ:TNGX opened at $21.22 on Thursday. The business has a fifty day moving average of $14.76 and a 200-day moving average of $10.97. Tango Therapeutics, Inc. has a twelve month low of $1.03 and a twelve month high of $21.82. The firm has a market cap of $3.03 billion, a PE ratio of -24.39 and a beta of 1.30.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.30%. On average, analysts anticipate that Tango Therapeutics, Inc. will post -1.19 EPS for the current fiscal year.

Insider Buying and Selling at Tango Therapeutics

In other Tango Therapeutics news, insider Adam Crystal sold 54,345 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $12.77, for a total value of $693,985.65. Following the completion of the sale, the insider directly owned 132,873 shares in the company, valued at $1,696,788.21. This represents a 29.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Barbara Weber sold 30,519 shares of Tango Therapeutics stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total value of $374,162.94. Following the transaction, the director owned 1,629,254 shares in the company, valued at $19,974,654.04. This trade represents a 1.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 145,884 shares of company stock valued at $1,965,942. Company insiders own 7.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TNGX. Wedbush upped their target price on Tango Therapeutics from $15.00 to $19.00 and gave the company an “outperform” rating in a report on Friday, March 6th. Stifel Nicolaus upped their price target on Tango Therapeutics from $15.00 to $24.00 and gave the stock a “buy” rating in a research note on Monday, March 9th. Jefferies Financial Group reissued a “buy” rating and set a $18.00 price objective on shares of Tango Therapeutics in a report on Thursday, March 5th. Mizuho raised their price objective on shares of Tango Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tango Therapeutics in a research note on Wednesday, January 21st. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Tango Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $19.50.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.